Babol University of Medical Sciences Caspian Journal of Surgery 3115-9087 1 1 2025 03 01 Evaluation of Urgent Coronary Artery Bypass Grafting (CABG) Survival in Patients With Acute Myocardial Infarction 37 42 724791 10.22088/caspjs.2025.724791 EN Mehdi Tahmasbi Student Research Committee, Babol University of Medical Sciences, Babol, Iran 0009-0009-9723-3241 Kamyar Amin Department of Cardiology, School of Medicine, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran 0000-0002-5111-2059 Hamidreza Vafaee Department of Surgery, School of Medicine, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran 0000-0001-8267-820X Iraj Jafaripour Department of Cardiology, School of Medicine, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran 0000-0002-2702-1747 Hoda Shirafkan Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 0000-0002-5682-1153 Journal Article 2025 05 26 Background: Cardiovascular diseases are the leading cause of death in Iran and other countries. Due to the fact that in many centers, it is not possible to perform Urgent Coronary artery bypass grafting (UCABG) and the number of samples performed in other centers is low, so a similar study was not found in Iran. Therefore, the present study was performed to evaluate UCABG survival in patients with acute myocardial infarction. Materials and Methods: In this historical cohort study, all patients with acute myocardial infarction who referred to Ayatollah Rouhani Hospital during 2011-2018 and underwent UCABG were included in the study. This plan was presented in the Ethics Committee of Babol University of Medical Sciences. All patients to be fully followed-up include: 1. Major cardiovascular complications (including cardiac death, major bleeding, and re-MI), 2. Major adverse cardiovascular events, 3. Re-admission rate, and 4. Requirement for angiography and re-angioplasty that the consequences were also evaluable and their history and paraclinical information were included in the file. Results: The mean survival in non-diabetic patients was 55.81 (53.60-58.01) months and in diabetic patients was 56 (53.58-53.46) months which were not statistically significant (p= 0.48). The mean was 56.33 (54.27-39.39) months survival in patients without hypertension and was 55.32 (52.59-55.05) months in patients with hypertension, which was not statistically significant (p=0.40). The mean survival was 55.95 (54.24 - 57.66) months in patients without a history of MI during the first 3 years after surgery and was 54.14 (61.95-46.32) months in patients with a history of MI during the first 3 years after surgery which there did not have a statistically significant difference (p = 0.09). The mean survival was 55.99 (54.09-57.89) months in patients without a history of readmission and was 55.50 (52.01-58.98) months in patients with a history of readmission which were not statistically significant (p=0.33). The mean survival was 55.28 (53.13-57.42) months in men and was 56.95 (54.33-59.56) months in women which was not statistically significant (p = 0.19). According to Cox regression analysis, none of the variables was related to 5-year survival of patients. Conclusion: Based on the results of the present study, the mortality rate in patients undergoing UCABG was 18% over 5 years, which with a median survival of 56 months, had a good feedback in patients with acute myocardial infarction.

https://www.caspjs.com/article_724791_9fe8acc918636af0ec1feb032fe3d63f.pdf